<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383705</url>
  </required_header>
  <id_info>
    <org_study_id>DHF24491</org_study_id>
    <nct_id>NCT03383705</nct_id>
  </id_info>
  <brief_title>VBeam Prima for Treatment of Photoaged Facial Skin</brief_title>
  <official_title>VBeam Prima for Treatment of Photoaged Facial Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-center study. Subjects in this study will receive up to four&#xD;
      (4) facial treatments at 4-6 (±1) weeks interval, with the VBeam Prima device according to&#xD;
      the study protocol. Subjects will return for follow-up (FU) visits at the clinic at 1 and 3&#xD;
      months following the last treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">November 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Improvement Scale</measure>
    <time_frame>1 or 3 months post last treatment</time_frame>
    <description>Overall improvement using Global Improvement Scale (0=no response; 4=excellent response).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wrinkle and Elastosis Score</measure>
    <time_frame>Pre Tx.4, 1 month and 3 months post final treatment</time_frame>
    <description>Improvement using Fitzpatrick Wrinkle Class and Elastosis Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment discomfort based on NRS Scale</measure>
    <time_frame>Immediately post treatment</time_frame>
    <description>Evaluate treatment discomfort based on NRS Scale as reported by study subjects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Photoaged Facial Skin</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VBeam Prima</intervention_name>
    <description>Up to four treatments will be performed every 4-6 (±1) weeks.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy Male or Female at least 18 years of age&#xD;
&#xD;
          2. Photoaged facial skin with clinically visible background erythema, telangiectasia, or&#xD;
             pigmented lesions&#xD;
&#xD;
          3. Fitzpatrick Elastosis Score 2-9&#xD;
&#xD;
          4. Fitzpatrick Skin Type I - VI&#xD;
&#xD;
          5. Able to read, understand and sign the Informed Consent Form&#xD;
&#xD;
          6. Willing and able to adhere to the treatment and follow-up schedule and post-treatment&#xD;
             care instructions&#xD;
&#xD;
          7. Willing to have limited sun exposure for the duration of the study, including the&#xD;
             follow-up period&#xD;
&#xD;
          8. Willing to have photographs taken of the treated area which will be used,&#xD;
             de-identified, in evaluations and may be used, de-identified, in presentations and/or&#xD;
             publications&#xD;
&#xD;
          9. For female candidates - subject must be post-menopausal, or surgically sterilized, or&#xD;
             using a medically acceptable form of birth control during the entire course of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or planning to become pregnant during the study duration.&#xD;
&#xD;
          2. Implant in the treated area (such as metal plates or screws) or an injected chemical&#xD;
             substance.&#xD;
&#xD;
          3. Known collagen (connective tissue) disorder, vascular disease (i.e. saphenous reflux),&#xD;
             scleroderma or other autoimmune disease (i.e. rheumatoid arthritis, lupus).&#xD;
&#xD;
          4. History of diseases stimulated by heat or sun exposure, such as recurrent Herpes&#xD;
             Simplex in the treated area, unless treatment is conducted following a prophylactic&#xD;
             regimen.&#xD;
&#xD;
          5. History of immunosuppression/immune deficiency disorders (including HIV infection or&#xD;
             AIDS) or currently using immunosuppressive medications.&#xD;
&#xD;
          6. Undergoing any form of treatment for active cancer, or having a history of skin cancer&#xD;
             or any other cancer in the areas to be treated, including actinic keratosis, presence&#xD;
             of malignant or pre-malignant pigmented lesions.&#xD;
&#xD;
          7. Significant concurrent illness, such as such as cardiac disorders, diabetes (type I or&#xD;
             II), or pertinent neurological disorders.&#xD;
&#xD;
          8. Infection or are suffering from a current or a history of significant skin conditions&#xD;
             in the treated area and/or inflammatory skin conditions, including, but not limited&#xD;
             to: photodermatoses, psoriasis, eczema, rash, severe open wound stage rosacea, open&#xD;
             cuts or scrapes and active cold sores or herpes sores prior to study treatment or&#xD;
             during the study treatment course.&#xD;
&#xD;
          9. Anticoagulative or thromboembolic condition or taking anticoagulation medications one&#xD;
             week prior to and during the treatment course (to allow inclusion, temporary cessation&#xD;
             of use might be requested as per the subject's physician discretion).&#xD;
&#xD;
         10. Use of aspirin or pain relievers from the ibuprofen family (e.g., Motrin®, Advil®, or&#xD;
             Naprosyn®) on a regular basis or would be taking any of these pain relievers one week&#xD;
             before and after each study treatment session.&#xD;
&#xD;
         11. History of keloid scarring or of abnormal wound healing.&#xD;
&#xD;
         12. Photosensitivity to the device's laser wavelengths, history of ingesting medications&#xD;
             known to induce photosensitivity, or history of seizure disorders due to light.&#xD;
&#xD;
         13. Surgical, light-based therapy or RF procedures in the treatment area within 3 months&#xD;
             of treatment or during the study.&#xD;
&#xD;
         14. Any other surgery in the treated area within 3 months of treatment (or more if skin&#xD;
             has not healed completely) or during the study.&#xD;
&#xD;
         15. Tattoo or permanent make-up in the treated area.&#xD;
&#xD;
         16. Systemica use of retinoids (i.e. Retin-A®, Accutane®) or antioxidants (i.e.&#xD;
             Restylane®, Strivectin®) within 2 months of study treatment or during the study.&#xD;
&#xD;
         17. Excessive tan in areas to be treated or unable/unlikely to refrain from tanning during&#xD;
             the study.&#xD;
&#xD;
         18. Participation in a study of another device or drug within three months prior to&#xD;
             enrollment or during the study.&#xD;
&#xD;
         19. As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gilly Munavalli, MD</last_name>
    <phone>(704) 375-6766</phone>
    <email>info@carolinaskin.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy Tucker, RN-C</last_name>
    <phone>(704) 375-6766</phone>
    <email>info@carolinaskin.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Tucker, RN-C</last_name>
      <phone>704-375-6766</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Photoaged Skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

